Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update Portfolio News / By Karina Tin November 10, 2022 Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update Read More »
Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies Portfolio News / By Karina Tin November 10, 2022 Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies Read More »
eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update Portfolio News / By Karina Tin November 7, 2022 eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update Read More »
ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update Portfolio News / By Karina Tin November 7, 2022 ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update Read More »
Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress Portfolio News / By Karina Tin November 7, 2022 Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress Read More »
A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022 Portfolio News / By Karina Tin November 7, 2022 A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022 Read More »
NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results Portfolio News / By Karina Tin November 3, 2022 NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results Read More »
NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Society Annual Scientific Meeting Portfolio News / By Karina Tin November 3, 2022 NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Society Annual Scientific Meeting Read More »
Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit Portfolio News / By Karina Tin October 26, 2022 Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit Read More »
eFFECTOR Completes Enrollment in Second of Three Cohorts of Phase 1B Clinical Trial of Zotaifin for the Treatment of Covid-19 Portfolio News / By Karina Tin October 26, 2022 eFFECTOR Completes Enrollment in Second of Three Cohorts of Phase 1B Clinical Trial of Zotaifin for the Treatment of Covid-19 Read More »
